Trial Profile

The effect of weekly rifapentine and isoniazid (3HP), compared to 4 months of daily rifampicin (4RIF) upon adherence with treatment for latent TB infection

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isoniazid (Primary) ; Rifapentine (Primary) ; Rifampicin
Indications Tuberculosis
Focus Therapeutic Use

Most Recent Events

18 Feb 2022 Recruitment completion is expected on 30/11/2022 according to Australian New Zealand Clinical Trials Registry record
18 Feb 2022 Planned End Date changed from 30 Apr 2022 to 30 Apr 2023.
19 Feb 2021 Planned number of patients changed from 322 to 210.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com